

# Tatsuaki Takeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7119902/publications.pdf>

Version: 2024-02-01

7  
papers

109  
citations

1684188

5  
h-index

1872680

6  
g-index

7  
all docs

7  
docs citations

7  
times ranked

177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE, 2017, 12, e0171356.	2.5	33
2	Acquired resistance mechanisms to afatinib in <i>HER2</i> -amplified gastric cancer cells. Cancer Science, 2019, 110, 2549-2557.	3.9	26
3	Therapeutic strategies for afatinib-resistant lung cancer harboring <i>HER2</i> alterations. Cancer Science, 2018, 109, 1493-1502.	3.9	23
4	YES1 activation induces acquired resistance to neratinib in <i>HER2</i> -amplified breast and lung cancers. Cancer Science, 2020, 111, 849-856.	3.9	15
5	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic <i>BRAF</i> Mutation. Anticancer Research, 2020, 40, 2667-2673.	1.1	6
6	YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. International Journal of Molecular Sciences, 2021, 22, 12809.	4.1	6
7	Drug interaction (52. Drug interaction with diuretics). Okayama Igakkai Zasshi, 2021, 133, 189-194.	0.0	0